Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN Symposium 2018 /
Precision CAR T cell therapeutics

25th - 26th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.18
Views: 1519

Prof Carl H. June - Perelman School of Medicine, Philadelphia, USA

Prof June speaks with ecancer at the 2018 WIN symposium about using CAR-T cells in leukaemia and lymphoma.

He describes how CAR-T cells are a 'living drug' and the process is similar to that of a bone marrow transplant.

He touches upon some of the reactions to CAR-T such as cytokine release syndrome, noting its management with IL-6 agonist tocilizumab.

Prof June finishes by describing some of the challenges ahead, and also some of the potential possibilities in the distant future.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation